Please select the eligibility criteria that correspond to the clinical trial below.
Title: Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence
Brief Summary: During transcutaneous mechanical nerve stimulation in spinal cord injured men an increase in pressure was observed in the external urethral sphincter along with an increase in bladder capacity. In a subsequent study it was demonstrated that Transcutaneous Mechanical Nerve Stimulation (TMNS) in women could induce pressure increment of the external urethral sphincter. A pilot study have since shown that after 6 weeks of stimulation 24 out of 33 women suffering from urinary stress incontinence were able to contract their pelvic floor muscles and had become free of symptoms. Another pilot study has shown promising effect on the overactive bladder syndrome. Furthermore pilot studies in men who are incontinent after a radical prostatectomy have shown promising results. A randomized investigation of TMNS applied in the immediate period after a radical prostatectomy to investigate effects on both continence and erectile function is on going.

The present study aims to treat urinary incontinence in men who are still incontinent more than 1 year after a radical prostatectomy. A medical vibrator is used daily for a period of 6 weeks and the results of the treatment is then evaluated. The participants will be randomized to 2 groups. Group 1 starts vibration treatment at base line and group 2 starts after 6 weeks when group 1 is done. The groups are compared at baseline, at 6 weeks and at 12 weeks.

The stimulation will be performed at the frenulum of the glans penis every day for 6 weeks with an amplitude of 2 mm and a frequency of 100 Hz. Results will be evaluated on the basis of questionnaires, micturition diaries and diaper tests.

If the investigators are able to demonstrate a significant reduction in the incontinence symptoms in the subjects the investigators asses that vibration can be a way of reestablishing normal continence in men after a radical prostatectomy.


Options:
A: Inclusion Criteria:

* Men who have undergone a radical prostatectomy at least 1 year prior to enrollment
* Incontinence induced by the surgery (at least 8 g/24 hours)
* Capable of understanding study information and following treatment

Exclusion Criteria:

* Incontinence before radical prostatectomy
* Treatment with anticholinergic medications
* Radiation or hormone treatment
* Previous surgical treatment of incontinence
* Acute illness (including infection, trauma and haematuria)
* Faecal incontinence
* Known neurological disease
* Known Bladder pathology on cystoscopy
B: Inclusion Criteria:

* patients with urinary sphincter deficiency resulting from a radical prostatectomy surgery
* sent by urologists the same hospital where the experiment will take place
* having the maximum time six months after surgery
* to use 2 to 5 disposable protective per day

Exclusion Criteria:

* Symptoms of urinary tract infection
* symptoms of lower urinary tract obstruction
* anal fistula
* metallic implant in the body
* transurethral resection of prostate
* radiation therapy
* non-enforcement of the proposed treatment.
C: Inclusion Criteria:

1. Have been diagnosed with early stage (I-III) prostate cancer.
2. Have completed cancer treatments six months prior.
3. Presence of incontinence symptoms

Exclusion Criteria:

1. Receiving hormonal treatment.
2. Urinary tract infection or urinary retention.
3. Cognitive impairment.
4. Having an implant
D: Inclusion Criteria:

* Having undergone a radical prostatectomy surgical procedure.
* Presenting involuntary urine losses after radical prostatectomy intervention. (IU grade I, II or III)
* Do not exceed the year since the surgical intervention.
* Accept to participate in the study and grant signed informed consent.

Exclusion Criteria:

* Follow a pharmacological treatment for the UI.
* Presenting anatomical malformations of the pelvic floor musculature.
* Carry pacemaker.
* Present anal fistulas.
* suffer from serious psychic disorders.
* Presenting lower urinary tract infections.

Answer: A